Belgian biotechnology company, Paleo, is reorienting its focus towards research and development (R&D) amidst challenging market conditions marked by slow regulatory approval processes and decreased investor interest in high-risk biotech ventures. Despite these obstacles, Paleo remains confident in its technology's potential to create animal-free proteins that replicate the taste and experience of meat. CEO Hermes Sanctorum emphasized the importance of maintaining core R&D efforts in response to the current market and funding environment, leading to a reduction in the company's workforce at its R&D Center in Leuven, Belgium.

Paleo specializes in developing animal-free heme proteins, crucial components in plant-based meat and fish products, aimed at enhancing flavor and authenticity. Recent collaborations, such as the partnership with Revo Foods to create animal-free salmon heme, highlight the company's commitment to innovation in the protein sector. Sanctorum believes that these tough decisions are necessary for sustaining Paleo's innovation and making a lasting impact on the food industry, despite the challenges faced in the market.